Toward a Comprehensive Bottom-up and Top-down Analysis of the NIST Reference Monoclonal Antibody
Poster Oct 26, 2014
Chris Becker1, Eric Carlson1, Wilfred Tang1, Yong Kil1, Marshall Bern1, John Schiel2, Lisa Kilpatrick2, Trina Formolo2
Careful characterization of therapeutic proteins is required due to their inherent variability. A reference protein standard can represent a major analytical tool for the industry, but it must be well-characterized in order to serve as a reference. In this study, high resolution mass spectrometric data of the NIST mAb interim reference material (RM 8670, lot 3F1b) was analyzed by new bioinformatics tools to efficiently identify and quantify modifications, including oxidation, deamidation, glycation, glycosylation, and sequence variants.
Heavy and light chain components were measured by both bottom-up and top-down (sometimes called middle-down) approaches by a high resolution Thermo Fisher Orbitrap Elite mass spectrometer employing CID, HCD and ETD fragmentation modes. The data was analyzed by a combination of the search engine Byonic™ and new inspection software Byologic® that combines and compares MS1 and MS2 data streams and performs label-free quantification by taking the ratio of extracted ion chromatograms (XICs) of the modified to unmodified peptide. In addition, new peptide mapping software, Byomap™, was employed to quantify and annotate the peptide map.
Bottom-up analysis with just a few data sets led to extensive site-specific identification and quantification of sequence variants, glycations, glycosylations, oxidations, and deamidations. Glycosylation (both bottom-up and top-down) was measured for the intact molecular forms. The top-down analysis by Byonic provided annotation of fragments spanning the entire sequences, with ETD, at least initially, providing the greatest degree of fragment coverage. Oxidation sites, glycosylation and truncations were observed in the top-down analysis. Overall, with a modest amount of high quality mass spectra, extensive quantitative analysis of the NIST interim reference standard was performed in a rapid fashion.
Histone Deacetylase 6 (HDAC6) As A Therapeutic Target in Chronic Lymphocytic LeukemiaPoster
This study investigates the role of histone deacetylase 6 (HDAC6) in chronic lymphocytic leukemia and establishes it as a novel therapeutic target for the treatment of this disease.READ MORE
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell ImmunotherapiesPoster
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.READ MORE
Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint ImmunotherapyPoster
Cell-based reporter bioassays overcome the limitations of primary cell-based assays for functional characterization of antibody and other biologics drugs targeting individual or combination immune checkpoint receptors. Here we show a portfolio of immune inhibitory checkpoint bioassays targeting PD-1/PD-L1, TIGIT/CD155, CTLA4/CD80/86 and LAG3/MHCII, that can be used for antibody screening, characterization, potency and stability studies.READ MORE